



GESUNDHEIT

7. AUSSCHREIBUNG

7. EU-RAHMENPROGRAMM FÜR FORSCHUNG, TECHNOLOGISCHE ENTWICKLUNG UND DEMONSTRATION (2007-2013)

Veröffentlichung:

Vor-Veröffentlichung 4. April 2012
offizielle Veröffentlichung voraus. 12. Juli 2012

Einreichfristen:

FP7-HEALTH-2013-INNOVATION-1

1. Stufe: voraus. 2. Oktober 2012
2. Stufe: voraus. Februar 2013

FP7-HEALTH-2013-INNOVATION-2

1. Stufe: voraus. 25. September 2012
2. Stufe: voraus. Dezember 2012

ACHTUNG! Die Themen können sich noch ändern!

0. Horizontal Topics for collaborative projects relevant for the whole of theme health

HEALTH.2013.0-1: Boosting the translation of health research projects' results into innovative applications for health. [INNOVATION-2](#)

1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

1.1. High-throughput research

Closed

1.2 Detection, diagnosis and monitoring

HEALTH.2013.1.2-1: Development of imaging technologies for therapeutic interventions in rare diseases. INNOVATION-1

1.3 Suitability, safety, efficacy of therapies

HEALTH.2013.1.3-1: Modelling toxic responses in case studies for predictive human safety assessment. INNOVATION-1

HEALTH.2013.1.3-2: Innovative approaches to address adverse immune reactions to biomedical devices, implants and transplant tissues. INNOVATION-1

HEALTH.2013.1.3-3: Safety and efficacy of therapeutic vaccines. INNOVATION-1

HEALTH.2013.1.3-4: Development of alternative *in vitro*, analytical, immunochemical, and other test methods for quality control of vaccines. INNOVATION-1

1.4 Innovative therapeutic approaches and interventions

HEALTH.2013.1.4-1: Controlling differentiation and proliferation in human stem cells intended for therapeutic use. INNOVATION-1

2. TRANSLATING RESEARCH FOR HUMAN HEALTH

2.1. Integrating biological data and processes: large-scale data gathering, systems biology

2.1.1. Large-Scale Data Gathering

- HEALTH.2013.2.1.1-1: Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes. INNOVATION-1
- HEALTH.2013.2.1.1-2: High impact research initiative on metagenomics for personalised medicine approaches. INNOVATION-1

2.1.2. Systems Biology

Closed

2.2. Research on the brain and related diseases, human development and ageing

2.2.1. Brain and brain-related diseases

- HEALTH.2013.2.2.1-1: Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI). INNOVATION-1
- HEALTH.2013.2.2.1-2: Development of effective imaging tools for diagnosis, monitoring and management of mental disorders. INNOVATION-1
- HEALTH.2013.2.2.1-3: Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment. INNOVATION-1
- HEALTH.2013.2.2.1-4: Patho-physiology and therapy of epilepsy and epileptiform disorders. INNOVATION-1
- HEALTH.2013.2.2.1-5: Understanding and controlling pain. INNOVATION-1

2.2.2. Human development and ageing

Closed

2.3. Translational research in major infectious diseases: to confront major threats to public health

2.3.0. Cross-Cutting

- HEALTH.2013.2.3.0-1: Innovation in vaccines. INNOVATION-1

2.3.1. Anti-microbial drug resistance

- HEALTH.2013.2.3.1-1: Drugs and vaccines for infections that have developed or are at the risk of developing significant anti-microbial resistance. [INNOVATION-2](#)
- HEALTH.2013.2.3.1-2: Stratified approaches to antibacterial and/or antifungal treatment. INNOVATION-1

2.3.2. HIV/AIDS, malaria and tuberculosis

Closed

2.3.3. Potentially new and re-emerging epidemics

- HEALTH.2013.2.3.3-1: Clinical management of patients in severe epidemics. INNOVATION-1

2.3.4. Neglected infectious diseases

Health.2013.2.3.4-1: Neglected infectious diseases of Central and Eastern Europe. INNOVATION-1

Health.2013.2.3.4-2: Drug development for neglected parasitic diseases. INNOVATION-1

2.4. Translational research in other major diseases

2.4.1. Cancer

HEALTH.2013.2.4.1-1: Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer. INNOVATION-1

HEALTH.2013.2.4.1-2: Strengthening the cancer patient's immune system. INNOVATION-1

HEALTH.2013.2.4.1-3: Investigator-driven supportive and palliative care clinical trials and observational studies. INNOVATION-1

2.4.2. Cardiovascular diseases

HEALTH.2013.2.4.2-1: Discovery research to reveal novel targets for cardiovascular disease treatment. INNOVATION-1

HEALTH.2013.2.4.2-2: Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases. INNOVATION-1

HEALTH.2013.2.4.2-3: Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan. INNOVATION-1

2.4.3. Diabetes and obesity

Closed

2.4.4. Rare diseases

Closed

2.4.5. Other chronic diseases

Closed

3. OPTIMISING THE DELIVERY OF HEALTH CARE TO EUROPEAN CITIZENS

3.1 Translating the results of clinical research outcome into clinical practice including better use of medicines, appropriate use of behavioural and organisational interventions and new health therapies and technologies

HEALTH.2013.3.1-1: Comparative Effectiveness Research (CER) in health systems and health services interventions. INNOVATION-1

3.2. Quality, efficiency and solidarity of health care systems including transitional health systems

Closed

3.3. Health promotion and prevention

HEALTH.2013.3.3-1: Social innovation for health promotion. INNOVATION-1

3.4. International public health & health systems

Closed

4. OTHER ACTIONS ACROSS THE HEALTH THEME

4.1. Coordination and support actions across the theme

- HEALTH.2013.4.1-1: Supporting industrial participation in EU-funded research in the Health sector. INNOVATION-1
- HEALTH.2013.4.1-2: Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation. INNOVATION-1
- HEALTH.2013.4.1-3: Support for Presidency events: Organisation of supporting actions and events associated to the Presidency of the European Union. INNOVATION-1
- HEALTH.2013.4.1-4: Preparing the future for health research and innovation. INNOVATION-1
- HEALTH.2013.4.1-5: Global initiative on gene-environment interactions in diabetes/obesity in specific populations. INNOVATION-1
- HEALTH.2013.4.1-6: Mapping chronic non-communicable diseases research activities. INNOVATION-1

4.2. Responding to EU policy needs

- HEALTH.2013-4.2-1: Investigator-driven clinical trials for off-patent medicines using innovative, age-appropriate formulations and/or delivery systems. INNOVATION-1
A) for use in children (Regulation (EC) No1901/2006):
B) for use in the elderly
- HEALTH.2013.4.2-2: Adverse drug reaction research. INNOVATION-1
- HEALTH.2013.4.2-3: New methodologies for clinical trials for small population groups. INNOVATION-1

ART DER FÖRDERUNG UND FÖRDERHÖHE

- **Forschungsprojekte:**

Forschungsaktivitäten:	50-75 % der förderungswürdigen Kosten, je nach Organisation
Demonstrationsaktivitäten:	max. 50 % der förderungswürdigen Kosten
Management, andere Aktivitäten:	max. 100 % der förderungswürdigen Kosten
- **Koordinierungs- und Unterstützungsmaßnahmen:** max. 100 % des Budgets

LINKS

<http://rp7.ffg.at/health>, <http://cordis.europa.eu/fp7/health>

KONTAKT

Dr. Astrid Hoebertz – Nationale Kontaktstelle
Tel.: +43 (0)5 7755 – 4104
E-mail: astrid.hoebertz@ffg.at

Mag. Nicole Firnberg - Expertin
Tel.: +43 (0)5 7755 – 4107
E-mail: nicole.firnberg@ffg.at

Informationsstand 23. April 2012 - alle Angaben ohne Gewähr